TearLab Corporation Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/15/2020)
| Balance Sheet | Total Assets | 14,293,000.00 | ROE | – |
| Balance Sheet | Total Equity | -26,021,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -411,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -1,365,000.00 | – | – |
| Cashflow | Operating Cash Flow | -954,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.44 | Div. Yield | – |
| Income | Net Income | -5,416,000.00 | P/E | – |
| Income | Shares Outstanding | 12,309,100.00 | P/B | – |
| Income | Total Revenue | 22,655,000.00 | P/S | – |
Ratios calculated on: –
Company Description
TearLab Corp. is an in-vitro diagnostic company. The Company is commercializing a tear testing platform, the TearLab Osmolarity System that enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company´s first product measures tear film osmolarity for the diagnosis of Dry Eye Disease (DED). TearLab Research, Inc., its wholly owned subsidiary, develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites (i.e. glucose), genes and proteins) at the point-of-care. Commercializing that tear testing platform is the focus of the Company´s business. Its TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor´s office. The TearLab Osmolarity System consists of three components: the TearLab disposable, the TearLab Pen and the TearLab Reader.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.tearlab.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more